These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2573 related articles for article (PubMed ID: 29773717)

  • 61. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
    Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L
    Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
    Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F
    Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases.
    Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
    J Thorac Oncol; 2015 Mar; 10(3):531-4. PubMed ID: 25695224
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify
    Talwelkar SS; Nagaraj AS; Devlin JR; Hemmes A; Potdar S; Kiss EA; Saharinen P; Salmenkivi K; Mäyränpää MI; Wennerberg K; Verschuren EW
    Mol Cancer Ther; 2019 Oct; 18(10):1863-1874. PubMed ID: 31320402
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Novel activating KRAS mutation candidates in lung adenocarcinoma.
    Abe J; Tanuma N; Nomura M; Ito S; Kasugai I; Sato I; Tamai K; Mochizuki M; Yamaguchi K; Shima H; Okada Y; Yasuda J
    Biochem Biophys Res Commun; 2020 Feb; 522(3):690-696. PubMed ID: 31787238
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
    Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
    Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
    Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
    Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
    Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
    J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8
    Peng DH; Rodriguez BL; Diao L; Chen L; Wang J; Byers LA; Wei Y; Chapman HA; Yamauchi M; Behrens C; Raso G; Soto LMS; Cuentes ERP; Wistuba II; Kurie JM; Gibbons DL
    Nat Commun; 2020 Sep; 11(1):4520. PubMed ID: 32908154
    [TBL] [Abstract][Full Text] [Related]  

  • 71. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence.
    Mitchell KG; Parra ER; Zhang J; Nelson DB; Corsini EM; Villalobos P; Moran CA; Skoulidis F; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    Ann Thorac Surg; 2020 Oct; 110(4):1131-1138. PubMed ID: 32442617
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.
    Boumelha J; de Castro A; Bah N; Cha H; de Carné Trécesson S; Rana S; Tomaschko M; Anastasiou P; Mugarza E; Moore C; Goldstone R; East P; Litchfield K; Lee SH; Molina-Arcas M; Downward J
    Cancer Res; 2024 Jul; 84(14):2231-2246. PubMed ID: 38635884
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
    Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
    Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of
    Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
    JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
    Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
    J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
    Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Primary Resistance to Immune Checkpoint Blockade in an
    Kwack WG; Shin SY; Lee SH
    Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    Pons-Tostivint E; Lugat A; Fontenau JF; Denis MG; Bennouna J
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831355
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
    Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
    Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 129.